Claes Andersson Selected Research

alpha-Mannosidosis

10/2017	Long-term enzyme replacement therapy improves neurocognitive functioning and hippocampal synaptic plasticity in immune-tolerant alpha-mannosidosis mice.
11/2015	Chronic enzyme replacement therapy ameliorates neuropathology in alpha-mannosidosis mice.
1/2010	Impaired lysosomal trimming of N-linked oligosaccharides leads to hyperglycosylation of native lysosomal proteins in mice with alpha-mannosidosis.
11/2008	Reversal of peripheral and central neural storage and ataxia after recombinant enzyme replacement therapy in alpha-mannosidosis mice.
9/2004	Efficacy of enzyme replacement therapy in alpha-mannosidosis mice: a preclinical animal study.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Claes Andersson Research Topics

Disease

5	Neoplasms (Cancer) 01/2022 - 08/2013
5	alpha-Mannosidosis 10/2017 - 09/2004
5	Lysosomal Storage Diseases (Lysosomal Storage Disease) 11/2015 - 04/2008
3	Alcoholism (Alcohol Abuse) 01/2018 - 09/2007
3	Metachromatic Leukodystrophy (Sulfatide Lipidosis) 02/2010 - 04/2008
2	Colorectal Neoplasms (Colorectal Cancer) 01/2022 - 04/2011
2	Colonic Neoplasms (Colon Cancer) 07/2018 - 11/2017
2	Nervous System Diseases (Neurological Disorders) 11/2015 - 04/2009
1	Hepatocellular Carcinoma (Hepatoma) 01/2022
1	Multiple Myeloma 12/2021
1	Bone Resorption 12/2021
1	Binge Drinking 01/2020
1	Carcinoma (Carcinomatosis) 12/2017
1	Infections 08/2017
1	Gliosis 09/2015
1	Demyelinating Diseases (Demyelinating Disease) 09/2015
1	Globoid Cell Leukodystrophy (Krabbe Disease) 09/2015
1	Neuroinflammatory Diseases 09/2015
1	Substance-Related Disorders (Drug Abuse) 01/2014
1	Panic Disorder (Panic Attack) 01/2014
1	Social Phobia 01/2014
1	Leukemia 08/2013
1	Lymphoid Leukemia 08/2013
1	Glioblastoma (Glioblastoma Multiforme) 08/2013
1	Ataxia (Dyssynergia) 11/2008
1	Sphingolipidoses (Sphingolipidosis) 04/2008
1	Acute Intermittent Porphyria (Porphyria, Acute) 04/2006
1	Body Weight (Weight, Body) 09/2004

Drug/Important Bio-Agent (IBA)

6	Pharmaceutical PreparationsIBA 01/2020 - 08/2013
5	alpha-Mannosidase (LAMAN)IBA 10/2017 - 09/2004
4	AcidsIBA 10/2017 - 09/2004
3	Biomarkers (Surrogate Marker)IBA 07/2018 - 04/2011
3	EnzymesIBA 11/2015 - 04/2009
3	OligosaccharidesIBA 11/2015 - 09/2004
3	Mannose (D-Mannose)IBA 11/2015 - 09/2004
3	Cerebroside-Sulfatase (Arylsulfatase A)IBA 02/2010 - 04/2008
2	Mebendazole (Anti-Worm)FDA Link 07/2018 - 08/2017
2	Proteins (Proteins, Gene)FDA Link 12/2017 - 04/2011
2	Drug CombinationsIBA 11/2017 - 08/2013
2	HydrolasesIBA 11/2015 - 04/2009
1	regorafenibIBA 01/2022
1	nitazoxanide (NTZ)FDA Link 01/2022
1	Sorafenib (BAY 43-9006)FDA Link 01/2022
1	melflufenIBA 12/2021
1	Melphalan (Alkeran)FDA LinkGeneric 12/2021
1	T-Cell Antigen Receptors (T-Cell Receptor)IBA 07/2018
1	Type 3 Cyclic Nucleotide PhosphodiesterasesIBA 12/2017
1	Psychosine (Galactosylsphingosine)IBA 09/2015
1	GalactosylceramidaseIBA 09/2015
1	Vincristine (Oncovin)FDA LinkGeneric 08/2013
1	VLX40IBA 08/2013
1	TubulinIBA 08/2013
1	ErbB Receptors (EGF Receptor)IBA 08/2013
1	2'- deoxythymidylyl- (3'- 5')- 2'- deoxyadenosine (d(AT))IBA 08/2013
1	NSC 23766IBA 08/2013
1	6- (4- (3- (methylsulfonyl)benzylamino)- 5- (trifluoromethyl)pyrimidin- 2- ylamino)- 3,4- dihydroquinolin- 2(1H)- oneIBA 08/2013
1	Imatinib Mesylate (Gleevec)FDA Link 08/2013
1	Gefitinib (Iressa)FDA Link 08/2013
1	Temozolomide (Temodar)FDA LinkGeneric 08/2013
1	CamptothecinIBA 08/2013
1	rac1 GTP-Binding ProteinIBA 08/2013
1	Focal Adhesion Protein-Tyrosine KinasesIBA 08/2013
1	lysosomal proteinsIBA 01/2010
1	Glycoproteins (Glycoprotein)IBA 01/2010
1	Cathepsin BIBA 01/2010
1	Polysaccharides (Glycans)IBA 01/2010
1	Man(3)GlcNAc(2)IBA 01/2010
1	Lysergic Acid Diethylamide (LSD)IBA 04/2009
1	Sulfoglycosphingolipids (Sulfatides)IBA 04/2008
1	AntibodiesIBA 04/2008
1	Blood Alcohol ContentIBA 09/2007
1	PorphobilinogenIBA 04/2006
1	Heme (Haem)IBA 04/2006
1	PorphyrinsIBA 04/2006

Therapy/Procedure

6	Enzyme Replacement Therapy 10/2017 - 09/2004
1	Aftercare (After-Treatment) 01/2018
1	Intravenous Injections 04/2008
1	Intravenous Administration 09/2004